Despite the financial implosion of the German biotechnology industry, European M&A has been surprisingly rare. Management has been reluctant to give up the dream as long as some cash remains in the company and, even when they've been willing to listen to acquisition ideas, they haven't liked the valuations they're offered.
Platform companies Procognia Ltd. and Sense Proteomic Ltd. were able to get around both issues, helped by their...




